deltatrials
Completed PHASE3 NCT00080288

Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Chronic SWSD

A 12 Week, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CEP 10953 (150 mg) as Treatment for Adults With Excessive Sleepiness Associated With Chronic Shift Work Sleep Disorder

Sponsor: Cephalon

Conditions Excessive Sleepiness Shift Work Sleep Disorder
Interventions Armodafinil 150 mg/day Placebo
Updated 6 times since 2017 Last updated: Jul 12, 2013 Started: Mar 31, 2004 Completion: Dec 31, 2004

Listed as NCT00080288, this PHASE3 trial focuses on Excessive Sleepiness and Shift Work Sleep Disorder and remains completed. Sponsored by Cephalon, it has been updated 6 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2022 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jan 2022 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Mar 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Cephalon
Data source: Teva Branded Pharmaceutical Products R&D, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.